Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O94830

UPID:
DDHD2_HUMAN

ALTERNATIVE NAMES:
DDHD domain-containing protein 2; KIAA0725p; SAM, WWE and DDHD domain-containing protein 1

ALTERNATIVE UPACC:
O94830; B3KWV2; B3KXB5; Q9H8X7

BACKGROUND:
The protein Phospholipase DDHD2, with alternative names including DDHD domain-containing protein 2 and KIAA0725p, is integral to phospholipid metabolism. It specifically hydrolyzes key phospholipids and binds to phosphatidylinositols, playing a pivotal role in the structural maintenance of the endoplasmic reticulum and Golgi apparatus. Its function is essential for the proper transport between these organelles and the plasma membrane.

THERAPEUTIC SIGNIFICANCE:
Linked to Spastic paraplegia 54, an autosomal recessive disorder characterized by progressive weakness and spasticity, Phospholipase DDHD2's involvement in this neurodegenerative disease underscores the importance of its study. Exploring the functions of Phospholipase DDHD2 offers promising avenues for developing novel therapeutic interventions for such debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.